osa tirzepatide 🚨‼️Study presented at @AmDiabetesAssn 🔴Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity 🔴 in those with moderate-to-severe + obesity, ⤵️ AHI, body weight, hypoxic burden, hsCRP & SBP People who stop using Treatments & Serums Jars:1 Jar

osa tirzepatide 🚨‼️Study presented at @AmDiabetesAssn 🔴Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity 🔴 in those with moderate-to-severe + obesity, ⤵️ AHI, body weight, hypoxic burden, hsCRP & SBP People who stop using Treatments & Serums Jars:1 Jar

People who stop using Mounjaro suffer reversal of health benefits, says study | Health | The Guardian

Week three is when my appetite started tapering off

Treatments & Serums

Jars:1 Jar

The primary mechanisms of action include: Enhancing insulin secretion from pancreatic beta cells in a glucose-dependent manner, meaning insulin is only released when blood glucose levels are elevated Suppressing glucagon release from pancreatic alpha cells, which reduces hepatic glucose production Slowing gastric emptying , which helps moderate post-meal blood glucose spikes Reducing appetite through central nervous system effects, leading to decreased caloric intake and weight loss Examples of GLP-1 receptor agonists available in the UK include exenatide (Byetta, Bydureon), liraglutide (Victoza for diabetes, Saxenda for weight management), dulaglutide (Trulicity), lixisenatide (Lyxumia), and semaglutide (Ozempic/Rybelsus for diabetes, Wegovy for weight management)